Objective: To detect the levels of interleukin 6(IL-6)and interleukin 17A(IL-17A)in serum in patients with polymyalgia rheumatic(PMR).In order to explore the potential value of IL-6 and IL-17 A in differentiating PMR from other rheumatic diseases which has similar clinical symptoms in the early stage of diseases,we explored the relationship between IL-6,IL-17 A and the disease activity of PMR.At the same time,the effect of different therapies on the level of IL-6 in PMR patients were observed.Methods: 16 primary,non-treated PMR patients were selected from June 2018 to October 2019 in Yi jishan hospital of wannan medical college.Clinical and laboratory data were collected.Another 32 age-,gender-matched rheumatoid arthritis(RA)patients were selected as control.Serum IL-6 and IL-17 A were detected by ELISA.Every patient had been received 10 mg prednisone and followed-up every month to measure the effect of treatment for six months.Results:1.ESR and CRP were increased in all PMR patients,and serum ferritin was increased in 62.5% PMR patients.2.There was no significant difference in serum IL-6 expression between PMR patients and RA controls(χ~2=0.807,P>0.05).3.The level of serum IL-6 in PMR patients can be tested at baseline.It could decrease after receiving treated.4.The expression of IL-17 A of PMR patients showed a significant difference from that of the RA control group(P < 0.05).5.Serum IL-17 A was not detected in PMR patients at baseline,and the expression of IL-17 A was not detected during the follow-up.6.Compared to the patients treated with GC only therapy,the level of IL-6 decreased significantly in patients who showed high level at baseline after receiving GC+MTX.Conclusion: IL-6 may play a role in the onset and development of PMR,and maybe relate to disease activity.The serum IL-6 concentration in PMR patients was lower than that in RA patients.IL-17 A perhaps not related to the pathogenesis of PMR.MTX may be effective to PMR patients. |